This part looks good
$Sangamo Therapeutics (SGMO.US)$ Consolidated net loss for the second quarter ended June 30, 2024 was $36.1 million, or $0.18 per share, compared to a net loss of $114.5 million, or $0.66 per share, for the same period in 2023
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
74483586 :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP 74483586 : Sadly revenue looking like it missed big? Hehehe
74483586 Trytosaveabit OP : I am still holding this piece of shit![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP 74483586 : Not the company’s fault that market makers ignored the SSR rule and sent shares off exchange! Or that SS’s attacked it with market makers help! But ok!